Jessica Kasamoto

@YaleCBB

[Raghav "RV" Sehgal @rv_sehgal]

This week will be all about pre-prints, kicking off with my debut as a corresponding author on a paper titled, "Epigenetic aging biomarkers are responsive: Insights from 51 longevity interventional studies in humans."

This study is the first of its kind, bringing together clinical trials and intervention studies focused on longevity to evaluate which interventions might systematically reduce epigenetic age. It examines 110 epigenetic aging biomarkers to identify those consistently responsive across various interventions. We hope this work encourages the aging biomarker field to rigorously test these biomarkers for responsiveness—since not all DNAm aging biomarkers respond to interventions, even if they may be prognostic. Additionally, it aims to shift the field toward using multiple responsive biomarkers together to assess whether an intervention genuinely reduces epigenetic age, potentially impacting healthspan or lifespan.

Interventional study DNA methylation data for this study was compiled at @Yale in the Albert Higgins-Chen lab in the @YaleCBB program using publicly available resources such as @NCBI GEO and @embl as well as private sources such as @TruDiagnostic , thanks to @RyanSmithEpiAge ,@VarunDw and Natàlia Carreras Gallo!

And this was a huge team effort which could have been complete with help from support from my amazing colleagues and co-authors @Dansb95, @JessicaKasamoto , Jenel Fraij Armstrong, John T. Gonzalez, @MarkovYaro and Ahana Priyanka!

Check out more details at the link below!

https://t.co/ha90nvEcSa